Anti-TAT226 Antibody represents a highly specialized recombinant monoclonal antibody specifically engineered to target the human tumor-associated antigenic target 226, also known as LYPD1, with exceptional binding affinity and selectivity, effectively facilitating the measurable detection and neutralization of target-positive malignant cells across various preclinical experimental models to evaluate the efficacy of antibody-drug conjugates during strictly monitored laboratory observation periods.